LRG1: an emerging player in disease pathogenesis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The secreted glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1) was first described as a key player in pathogenic ocular neovascularization almost a decade ago. Since then, an increasing number of publications have reported the involvement of LRG1 in multiple human conditions including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. The purpose of this review is to provide, for the first time, a comprehensive overview of the LRG1 literature considering its role in health and disease. Although LRG1 is constitutively expressed by hepatocytes and neutrophils,Lrg1−/−mice show no overt phenotypic abnormality suggesting that LRG1 is essentially redundant in development and homeostasis. However, emerging data are challenging this view by suggesting a novel role for LRG1 in innate immunity and preservation of tissue integrity. While our understanding of beneficial LRG1 functions in physiology remains limited, a consistent body of evidence shows that, in response to various inflammatory stimuli, LRG1 expression is induced and directly contributes to disease pathogenesis. Its potential role as a biomarker for the diagnosis, prognosis and monitoring of multiple conditions is widely discussed while dissecting the mechanisms underlying LRG1 pathogenic functions. Emphasis is given to the role that LRG1 plays as a vasculopathic factor where it disrupts the cellular interactions normally required for the formation and maintenance of mature vessels, thereby indirectly contributing to the establishment of a highly hypoxic and immunosuppressive microenvironment. In addition, LRG1 has also been reported to affect other cell types (including epithelial, immune, mesenchymal and cancer cells) mostly by modulating the TGFβ signalling pathway in a context-dependent manner. Crucially, animal studies have shown that LRG1 inhibition, through gene deletion or a function-blocking antibody, is sufficient to attenuate disease progression. In view of this, and taking into consideration its role as an upstream modifier of TGFβ signalling, LRG1 is suggested as a potentially important therapeutic target. While further investigations are needed to fill gaps in our current understanding of LRG1 function, the studies reviewed here confirm LRG1 as a pleiotropic and pathogenic signalling molecule providing a strong rationale for its use in the clinic as a biomarker and therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Chronic inflammation in the etiology of disease across the life span
Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0675-0 · Cited by 4,915 · cited 1×
“Endothelial dysfunction is, among other factors, caused by chronic systemic low-grade inflammation, which is recognized by itself as a major risk factor for the development of cardiovascular disease [124].”
BackgroundWound repair and regeneration: Mechanisms, signaling, and translation
Eming, S. A., Martin, P., & Tomic-Canic, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009337 · Cited by 3,562 · cited 2×
“However, severe tissue damage, or the persistence of inflammatory stimuli, can cause aberrant cell signalling and either the formation of ulcerative defects (chronic wounds) or excessive ECM production (fibrosis) [60].”
BackgroundDiabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 1×
“It is well accepted that diabetes has injurious effects on the vasculature resulting in microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (coronary artery disease, peripheral arterial disease and stroke) complications which represent major causes of morbidity and mortality in diabetic patients…”
BackgroundMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing
Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., Lehr, H.-A., Hirth, S., Weigmann, B., Wirtz, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082683 · Cited by 1,043 · cited 8×
“As previously shown in the inflamed colon [28, 76], this study supports the hypothesis that mucosal epithelial cells represent a source of LRG1 during inflammatory reactions.”
BackgroundResultInfluential
Research works printed but not linked: 240
- Haupt H, Baudner S. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum (author’s transl). Hoppe Seylers Z Physiol Chem. 1977;358(6):639–46. · DOI · Paper page
- Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001;11(6):725–32. · DOI · Paper page
- Ng A, Xavier RJ. Leucine-rich repeat (LRR) proteins: integrators of pattern recognition and signaling in immunity. Autophagy. 2011;7(9):1082–4. · DOI · Paper page
- Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, et al. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013;499(7458):306–11. · DOI · Paper page
- Kallenberg D, Tripathi V, Javaid F, Pilotti C, George J, Davis S, et al. A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage. BioRxiv. 2020;55:137.
- Javaid F, Pilotti C, Camilli C, Kallenberg D, Bahou C, Blackburn J, et al. Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem Biol. 2021;2(4):1206–20. · DOI
- Takahashi N, Takahashi Y, Putnam FW. Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc Natl Acad Sci U S A. 1985;82(7):1906–10. · DOI · Paper page
- Jemmerson R. Paradoxical roles of leucine-rich α2-glycoprotein-1 in cell death and survival modulated by transforming growth factor-beta 1 and cytochrome c. Front Cell Dev Biol. 2021. https://doi.org/10.3389/fcell.2021.744908. · DOI
- Dolan J, Walshe K, Alsbury S, Hokamp K, O’Keeffe S, Okafuji T, et al. The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. BMC Genomics. 2007;8:320. · DOI · Paper page
- Kumagai S, Nakayama H, Fujimoto M, Honda H, Serada S, Ishibashi-Ueda H, et al. Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. Cardiovasc Res. 2016;109(2):272–82. · DOI
- Patwa TH, Zhao J, Anderson MA, Simeone DM, Lubman DM. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal Chem. 2006;78(18):6411–21. · doi:10.1021/ac060726z
- Shinozaki E, Tanabe K, Akiyoshi T, Tsuchida T, Miyazaki Y, Kojima N, et al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer. 2018;18(1):406. · DOI
- O’Donnell LC, Druhan LJ, Avalos BR. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol. 2002;72(3):478–85. · DOI · Paper page
- Honda H, Fujimoto M, Miyamoto S, Ishikawa N, Serada S, Hattori N, et al. Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma. PLoS ONE. 2016;11(9):e0162672. · DOI
- Honda H, Fujimoto M, Serada S, Urushima H, Mishima T, Lee H, et al. Leucine-rich alpha-2 glycoprotein promotes lung fibrosis by modulating TGF-beta signaling in fibroblasts. Physiol Rep. 2017. https://doi.org/10.14814/phy2.13556. · DOI
- Yang Y, Luo R, Cheng Y, Liu T, Dai W, Li Y, et al. Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis. BMC Nephrol. 2020;21(1):122. · DOI
- Liu C, Lim ST, Teo MHY, Tan MSY, Kulkarni MD, Qiu B, et al. Collaborative regulation of LRG1 by TGF-beta1 and PPAR-beta/delta modulates chronic pressure overload-induced cardiac fibrosis. Circ Heart Fail. 2019;12(12):e005962. · DOI
- Sng MK, Chan JSK, Teo Z, Phua T, Tan EHP, Wee JWK, et al. Selective deletion of PPARbeta/delta in fibroblasts causes dermal fibrosis by attenuated LRG1 expression. Cell Discov. 2018;4:15. · DOI
- Birsoy K, Berry R, Wang T, Ceyhan O, Tavazoie S, Friedman JM, et al. Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis. Development. 2011;138(21):4709–19. · DOI
- Zhang J, Ahn J, Suh Y, Hwang S, Davis ME, Lee K. Identification of CTLA2A, DEFB29, WFDC15B, SERPINA1F and MUP19 as novel tissue-specific secretory factors in mouse. PLoS ONE. 2015;10(5):e0124962. · DOI
- He S, Ryu J, Liu J, Luo H, Lv Y, Langlais PR, et al. LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance. J Clin Invest. 2021. https://doi.org/10.1172/JCI148545. · DOI
- Hong Q, Zhang L, Fu J, Verghese DA, Chauhan K, Nadkarni GN, et al. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-beta-Induced Angiogenesis. J Am Soc Nephrol. 2019;30(4):546–62. · DOI
- Haku S, Wakui H, Azushima K, Haruhara K, Kinguchi S, Ohki K, et al. Early Enhanced Leucine-Rich alpha-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice. Biomed Res Int. 2018;2018:2817045. · DOI
- Meng H, Song Y, Zhu J, Liu Q, Lu P, Ye N, et al. LRG1 promotes angiogenesis through upregulating the TGFbeta1 pathway in ischemic rat brain. Mol Med Rep. 2016;14(6):5535–43. · DOI
- Hughes K, Wickenden JA, Allen JE, Watson CJ. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J Pathol. 2012;227(1):106–17. · DOI
- Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, et al. Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells. Arthritis Res Ther. 2017;19(1):137. · DOI
- Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, et al. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res. 2014;74(23):6806–19. · DOI · Paper page
- Naka T, Fujimoto M. LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunol Med. 2018;41(2):62–7. · DOI
- Wang Y, Xu J, Zhang X, Wang C, Huang Y, Dai K, et al. TNF-alpha-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis. Cell Death Dis. 2017;8(3):e2715. · DOI · Paper page
- Makita N, Hizukuri Y, Yamashiro K, Murakawa M, Hayashi Y. IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration. Int Immunol. 2015;27(3):131–41. · DOI · Paper page
- Nitkin CR, Xia S, Menden H, Yu W, Xiong M, Heruth DP, et al. FOSL1 is a novel mediator of endotoxin/lipopolysaccharide-induced pulmonary angiogenic signaling. Sci Rep. 2020;10(1):13143. · doi:10.1038/s41598-020-69735-z
- Gao Y, Zhou J, Xie Z, Wang J, Ho CK, Zhang Y, et al. Mechanical strain promotes skin fibrosis through LRG-1 induction mediated by ELK1 and ERK signalling. Commun Biol. 2019;2:359. · DOI
- Fan M, Li C, He P, Fu Y, Li M, Zhao X. Knockdown of long noncoding RNA-taurine-upregulated gene 1 inhibits tumor angiogenesis in ovarian cancer by regulating leucine-rich alpha-2-glycoprotein-1. Anticancer Drugs. 2019;30(6):562–70. · DOI
- Naik A, Dalpatraj N, Thakur N. Global histone H3 lysine 4 trimethylation (H3K4me3) landscape changes in response to TGFbeta. Epigenet Insights. 2021;14:25168657211051756. · DOI
- Su Q, Lv XW, Sun YH, Ye ZL, Kong BH, Qin ZB. MicroRNA-494 inhibits the LRG1 expression to induce proliferation and migration of VECs in rats following myocardial infarction. Mol Ther Nucleic Acids. 2019;18:110–22. · DOI
- Luan L, Hu Q, Wang Y, Lu L, Ling J. Knockdown of lncRNA NEAT1 expression inhibits cell migration, invasion and EMT by regulating the miR-24-3p/LRG1 axis in retinoblastoma cells. Exp Ther Med. 2021;21(4):367. · DOI
- Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis. 2012;33(5):976–85. · DOI
- Gu Z, Xie D, Huang C, Ding R, Zhang R, Li Q, et al. MicroRNA-497 elevation or LRG1 knockdown promotes osteoblast proliferation and collagen synthesis in osteoporosis via TGF-beta1/Smads signalling pathway. J Cell Mol Med. 2020;24(21):12619–32. · DOI
- Lou T, Ke K, Zhang L, Miao C, Liu Y. LncRNA PART1 facilitates the malignant progression of colorectal cancer via miR-150-5p/LRG1 axis. J Cell Biochem. 2020;121(10):4271–81. · DOI
- Codina R, Vanasse A, Kelekar A, Vezys V, Jemmerson R. Cytochrome c-induced lymphocyte death from the outside in: inhibition by serum leucine-rich alpha-2-glycoprotein-1. Apoptosis. 2010;15(2):139–52. · DOI
- Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621–36. · DOI · Paper page
- Cummings C, Walder J, Treeful A, Jemmerson R. Serum leucine-rich alpha-2-glycoprotein-1 binds cytochrome c and inhibits antibody detection of this apoptotic marker in enzyme-linked immunosorbent assay. Apoptosis. 2006;11(7):1121–9. · DOI
- Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004;73(1):87–106. · DOI · Paper page
- Hao Z, Duncan GS, Chang C-C, Elia A, Fang M, Wakeham A, et al. Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell. 2005;121(4):579–91. · DOI · Paper page
- Xiao S, Zhu H. Leucine-Rich Alpha-2-Glycoprotein1 Gene Interferes with Regulation of Apoptosis in Leukemia KASUMI-1 Cells. Med Sci Monit. 2018;24:8348–56. · doi:10.12659/msm.911249
- Xie ZB, Zhang YF, Jin C, Mao YS, Fu DL. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. J Exp Clin Cancer Res. 2019;38(1):75. · DOI
- Zhou Y, Zhang X, Zhang J, Fang J, Ge Z, Li X. LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation. PLoS ONE. 2017;12(4):e0175122. · DOI
- Jemmerson R, Staskus K, Higgins L, Conklin K, Kelekar A. Intracellular leucine-rich alpha-2-glycoprotein-1 competes with Apaf-1 for binding cytochrome c in protecting MCF-7 breast cancer cells from apoptosis. Apoptosis. 2021;26(1–2):71–82. · DOI
- Weivoda S, Andersen JD, Skogen A, Schlievert PM, Fontana D, Schacker T, et al. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J Immunol Methods. 2008;336(1):22–9. · DOI
- Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils–forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2(9):500–10. · DOI · Paper page
- Ai J, Druhan LJ, Hunter MG, Loveland MJ, Avalos BR. LRG-accelerated differentiation defines unique G-CSFR signaling pathways downstream of PU.1 and C/EBPepsilon that modulate neutrophil activation. J Leukoc Biol. 2008;83(5):1277–85. · DOI
- Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30(11):538–46. · DOI · Paper page
- Liu C, Teo MHY, Pek SLT, Wu X, Leong ML, Tay HM, et al. A multifunctional role of leucine-rich alpha-2-glycoprotein 1 in cutaneous wound healing under normal and diabetic conditions. Diabetes. 2020;69(11):2467–80. · DOI
- Yu B, Yang L, Song S, Li W, Wang H, Cheng J. LRG1 facilitates corneal fibrotic response by inducing neutrophil chemotaxis via Stat3 signaling in alkali-burned mouse corneas. Am J Physiol Cell Physiol. 2021;321(3):C415–28. · DOI
- Moniruzzaman M, Wang R, Jeet V, McGuckin MA, Hasnain SZ. Interleukin (IL)-22 from IL-20 Subfamily of Cytokines Induces Colonic Epithelial Cell Proliferation Predominantly through ERK1/2 Pathway. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20143468. · DOI
- Yasutomi E, Inokuchi T, Hiraoka S, Takei K, Igawa S, Yamamoto S, et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep. 2021;11(1):11086. · DOI
- Gao Y, Xie Z, Ho C, Wang J, Li Q, Zhang Y, et al. LRG1 promotes keratinocyte migration and wound repair through regulation of HIF-1alpha stability. J Invest Dermatol. 2020;140(2):455-64.e8. · DOI
- Li W, Wang X, Cheng J, Li J, Wang Q, Zhou Q, et al. Leucine-rich alpha-2-glycoprotein-1 promotes diabetic corneal epithelial wound healing and nerve regeneration via regulation of matrix metalloproteinases. Exp Eye Res. 2020;196:108060. · DOI
- Rioux G, Pouliot-Berube C, Simard M, Benhassine M, Soucy J, Guerin SL, et al. The tissue-engineered human psoriatic skin substitute: a valuable in vitro model to identify genes with altered expression in lesional psoriasis. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19102923. · DOI
- Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–47. · DOI · Paper page
- Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S. The involvement of leucine-rich alpha-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Mod Rheumatol. 2021;31(6):1120–8. · DOI
- Hong Q, Cai H, Zhang L, Li Z, Zhong F, Ni Z, et al. Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich -2 glycoprotein-1. Kidney Int. 2021. https://doi.org/10.1016/j.kint.2021.10.023. · DOI
- Nystrom A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 2015;7(9):1211–28. · DOI · Paper page
- Mundo L, Tosi GM, Lazzi S, Pertile G, Parolini B, Neri G, et al. LRG1 expression is elevated in the eyes of patients with neovascular age-related macular degeneration. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22168879. · doi:10.3390/ijms22168879
- Zhou L, Shi DP, Chu WJ, Yang LL, Xu HF. LRG1 promotes epithelial-mesenchymal transition of retinal pigment epithelium cells by activating NOX4. Int J Ophthalmol. 2021;14(3):349–55. · DOI
- Liu TT, Luo R, Yang Y, Cheng YC, Chang D, Dai W, et al. LRG1 mitigates renal interstitial fibrosis through alleviating capillary rarefaction and inhibiting inflammatory and pro-fibrotic cytokines. Am J Nephrol. 2021;52(3):228–38. · doi:10.1159/000514167
- Pang KT, Ghim M, Liu C, Tay HM, Fhu CW, Chia RN, et al. Leucine-rich alpha-2-glycoprotein 1 suppresses endothelial cell activation through ADAM10-mediated shedding of TNF-alpha receptor. Front Cell Dev Biol. 2021;9:706143. · DOI
- Hisata S, Racanelli AC, Kermani P, Schreiner R, Houghton S, Palikuqi B, et al. Reversal of emphysema by restoration of pulmonary endothelial cells. J Exp Med. 2021. https://doi.org/10.1084/jem.20200938. · DOI
- Singhal M, Gengenbacher N, Pari AAA, Kamiyama M, Hai L, Kuhn BJ, et al. Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Sci Transl Med. 2021. https://doi.org/10.1126/scitranslmed.abe6805. · DOI · Paper page
- Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18(11):2169–79. · DOI · Paper page
- Zhong B, Cheng B, Huang X, Xiao Q, Niu Z, Chen YF, et al. Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling. Cell Death Dis. 2021;13(1):16. · DOI
- Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, Meerschaut S, et al. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood. 2006;108(2):575–83. · DOI · Paper page
- Beltran-Camacho L, Jimenez-Palomares M, Rojas-Torres M, Sanchez-Gomar I, Rosal-Vela A, Eslava-Alcon S, et al. Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia. Stem Cell Res Ther. 2020;11(1):106. · DOI
- Schlecht A, Thien A, Wolf J, Prinz G, Agostini H, Schlunck G, et al. Immunosenescence in Choroidal Neovascularization (CNV)—Transcriptional Profiling of Naïve and CNV-associated retinal myeloid cells during aging. Int J Mol Sci. 2021;22(24):13318. · DOI
- Jiang W, Xu C, Xu S, Su W, Du C, Dong J, et al. Macrophage-derived, LRG1-enriched extracellular vesicles exacerbate aristolochic acid nephropathy in a TGFbetaR1-dependent manner. Cell Biol Toxicol. 2021. https://doi.org/10.1007/s10565-021-09666-1. · doi:10.1007/s10565-021-09666-1
- Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002;21(7):1743–53. · DOI · Paper page
- Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004;23(20):4018–28. · DOI · Paper page
- O’Connor MN, Kallenberg DM, Camilli C, Pilotti C, Dritsoula A, Jackstadt R, et al. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med. 2021;2(11):1231-52.e10. · DOI
- Ban Z, He J, Tang Z, Zhang L, Xu Z. LRG1 enhances the migration of thyroid carcinoma cells through promotion of the epithelialmesenchymal transition by activating MAPK/p38 signaling. Oncol Rep. 2019;41(6):3270–80.
- de Garcia Vinuesa A, Abdelilah-Seyfried S, Knaus P, Zwijsen A, Bailly S. BMP signaling in vascular biology and dysfunction. Cytokine Growth Factor Rev. 2016;27:65–79. · DOI · Paper page
- Kwan YP, Teo MHY, Lim JCW, Tan MS, Rosellinny G, Wahli W, et al. LRG1 promotes metastatic dissemination of melanoma through regulating EGFR/STAT3 signalling. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13133279. · DOI
- Saito K, Tanaka T, Kanda H, Ebisuno Y, Izawa D, Kawamoto S, et al. Gene expression profiling of mucosal addressin cell adhesion molecule-1+ high endothelial venule cells (HEV) and identification of a leucine-rich HEV glycoprotein as a HEV marker. J Immunol. 2002;168(3):1050–9. · DOI
- Chen C, Chen X, Huang H, Han C, Qu Y, Jin H, et al. Elevated plasma and vitreous levels of leucine-rich-alpha2-glycoprotein are associated with diabetic retinopathy progression. Acta Ophthalmol. 2019;97(3):260–4. · DOI
- Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res. 2008;7(6):2516–25. · DOI · Paper page
- Hase K, Kanda A, Hirose I, Noda K, Ishida S. Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy. PLoS ONE. 2017;12(12):e0189696. · DOI
- Zhang X, Pek SLT, Tavintharan S, Sum CF, Lim SC, Ang K, et al. Leucine-rich alpha-2-glycoprotein predicts proliferative diabetic retinopathy in type 2 diabetes. J Diabetes Complications. 2019;33(9):651–6. · DOI
- Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, DosSantos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008;4(4):787–803.
- Kanda A, Ishida S. (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy. J Diabetes Investig. 2019;10(1):6–17. · DOI
- Song S, Cheng J, Yu BJ, Zhou L, Xu HF, Yang LL. LRG1 promotes corneal angiogenesis and lymphangiogenesis in a corneal alkali burn mouse model. Int J Ophthalmol. 2020;13(3):365–73. · DOI
- De Rossi G, Da Vitoria Lobo ME, Greenwood J, Moss SE. LRG1 as a novel therapeutic target in eye disease. Eye. 2022. https://doi.org/10.1038/s41433-021-01807-4. · DOI
- Zhang A, Fang H, Chen J, He L, Chen Y. Role of VEGF-A and LRG1 in Abnormal Angiogenesis Associated With Diabetic Nephropathy. Front Physiol. 2020;11:1064. · DOI
- Fu J, Wei C, Zhang W, Schlondorff D, Wu J, Cai M, et al. Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice. Kidney Int. 2018;94(2):326–45. · DOI
- Liu JJ, Pek SLT, Ang K, Tavintharan S, Lim SC, Study SD. Plasma leucine-rich alpha-2-glycoprotein 1 predicts rapid eGFR decline and albuminuria progression in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2017;102(10):3683–91. · DOI
- Gurung RL, Dorajoo R, Liu JJ, Pek SLT, Wang J, et al. Association of genetic variants for plasma LRG1 with rapid decline in kidney function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2021;106(8):2384–94. · DOI
- Kalantari S, Rutishauser D, Samavat S, Nafar M, Mahmudieh L, Rezaei-Tavirani M, et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS ONE. 2013;8(12):e80830. · DOI
- Suresh CP, Saha A, Kaur M, Kumar R, Dubey NK, Basak T, et al. Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome. Clin Exp Nephrol. 2016;20(2):273–83. · doi:10.1007/s10157-015-1162-7
- Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, et al. Leucine rich alpha-2 glycoprotein is a potential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun. 2018;498(4):1045–51. · DOI
- Ishida T, Kotani T, Serada S, Fujimoto M, Takeuchi T, Makino S, et al. Correlation of increased serum leucine-rich alpha2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study. PLoS ONE. 2020;15(6):e0234090. · DOI
- Shahzad T, Radajewski S, Chao CM, Bellusci S, Ehrhardt H. Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development. Mol Cell Pediatr. 2016;3(1):23. · DOI
- Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010;122(25):2727–35. · DOI · Paper page
- Feng J, Zhan J, Ma S. LRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1alpha. Bioengineered. 2021;12(1):8897–907. · DOI
- Ma S, Wang Y, Chen Y, Cao F. The role of the autophagy in myocardial ischemia/reperfusion injury. Biochim Biophys Acta. 2015;1852(2):271–6. · DOI · Paper page
- Song W, Wang X. The role of TGFbeta1 and LRG1 in cardiac remodelling and heart failure. Biophys Rev. 2015;7(1):91–104. · DOI
- Pek SL, Tavintharan S, Wang X, Lim SC, Woon K, Yeoh LY, et al. Elevation of a novel angiogenic factor, leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab. 2015;100(4):1586–93. · DOI
- Pek SLT, Cheng AKS, Lin MX, Wong MS, Chan EZL, Moh AMC, et al. Association of circulating proinflammatory marker, leucine-rich-alpha2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab Res Rev. 2018;34(7):e3029. · DOI
- Liu JJ, Pek SLT, Wang J, Liu S, Ang K, Shao YM, et al. Association of Plasma Leucine-Rich alpha-2 Glycoprotein 1, a Modulator of Transforming Growth Factor-beta Signaling Pathway, With Incident Heart Failure in Individuals With Type 2 Diabetes. Diabetes Care. 2021;44(2):571–7. · DOI
- Liu M, Koster LS, Fosgate GT, Chadwick CC, Sanz-Gonzalez I, Eckersall PD, et al. Cardiovascular-renal axis disorder and acute-phase proteins in cats with congestive heart failure caused by primary cardiomyopathy. J Vet Intern Med. 2020;34(3):1078–90. · DOI
- Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail. 2011;4(2):188–97. · DOI
- Tonry C, McDonald K, Ledwidge M, Hernandez B, Glezeva N, Rooney C, et al. Multiplexed measurement of candidate blood protein biomarkers of heart failure. ESC Heart Fail. 2021;8(3):2248–58. · DOI
- Zhang J, Zhang Y, Li N, Liu Z, Xiong C, Ni X, et al. Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir Med. 2009;103(12):1801–6. · doi:10.1016/j.rmed.2009.07.017
- Bos S, Phillips M, Watts GF, Verhoeven AJM, Sijbrands EJG, Ward NC. Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. J Clin Lipidol. 2017;11(3):682–93. · DOI
- Yin X, Subramanian S, Hwang SJ, O’Donnell CJ, Fox CS, Courchesne P, et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol. 2014;34(4):939–45. · DOI
- Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev. 2019;2019:7092151. · DOI · Paper page
- Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol. 2007;210(2):456–68. · DOI
- Yang FJ, Hsieh CY, Shu KH, Chen IY, Pan SY, Chuang YF, et al. Plasma leucine-rich alpha-2-glycoprotein 1 predicts cardiovascular disease risk in end-stage renal disease. Sci Rep. 2020;10(1):5988. · DOI
- Singh H, Yu Y, Suh MJ, Torralba MG, Stenzel RD, Tovchigrechko A, et al. Type 1 diabetes: urinary proteomics and protein network analysis support perturbation of lysosomal function. Theranostics. 2017;7(10):2704–17. · DOI
- Liu JJ, Pek SLT, Liu S, Wang J, Lee J, Ang K, et al. Association of plasma leucine-rich alpha-2 glycoprotein 1 (LRG1) with all-cause and cause-specific mortality in individuals with type 2 diabetes. Clin Chem. 2021. https://doi.org/10.1093/clinchem/hvab172. · DOI
- Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open. 2013;3(3):e002269. · DOI
- Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–203. · DOI · Paper page
- Karczewski J, Sledzinska E, Baturo A, Jonczyk I, Maleszko A, Samborski P, et al. Obesity and inflammation. Eur Cytokine Netw. 2018;29(3):83–94. · DOI · Paper page
- Rogler G. Significance of anti-inflammatory effects of PPARgamma agonists? Gut. 2006;55(8):1067–9. · DOI
- Aslam B, Basit M, Nisar MA, Khurshid M, Rasool MH. Proteomics: technologies and their applications. J Chromatogr Sci. 2017;55(2):182–96. · DOI · Paper page
- Ha YJ, Kang EJ, Lee SW, Park YB, Lee SK, Song JS, et al. Serum leucine-rich alpha2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still’s disease. Scand J Rheumatol. 2015;44(5):399–403. · DOI
- Nakajima H, Serada S, Fujimoto M, Naka T, Sano S. Leucine-rich alpha-2 glycoprotein is an innovative biomarker for psoriasis. J Dermatol Sci. 2017;86(2):170–4. · DOI
- Nakajima H, Nakajima K, Takaishi M, Ohko K, Serada S, Fujimoto M, et al. The skin-liver axis modulates the psoriasiform phenotype and involves leucine-rich alpha-2 glycoprotein. J Immunol. 2021;206(7):1469–77. · DOI
- Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, et al. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2056–60. · DOI
- Ha YJ, Kang E-J, Lee S-W, Lee S-K, Park Y-B, Song J-S, et al. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. J Korean Med Sci. 2014;29(9):1199–204. · DOI
- Jin E-H, Chae S-C, Shim SC, Kim HG, Chung H-T. Identification of human LRG1 polymorphisms and their genetic association with rheumatoid arthritis. Genom Inform. 2008;6:77–83. · DOI
- Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, et al. iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010;69(4):770. · DOI · Paper page
- Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada KE, et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 2017;19(1):218. · DOI
- Kimura Y, Yanagimachi M, Ino Y, Aketagawa M, Matsuo M, Okayama A, et al. Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis. Sci Rep. 2017;7:43732. · DOI
- Xie XF, Chu HJ, Xu YF, Hua L, Wang ZP, Huang P, et al. Proteomics study of serum exosomes in Kawasaki disease patients with coronary artery aneurysms. Cardiol J. 2019;26(5):584–93. · DOI
- Yanagimachi M, Fukuda S, Tanaka F, Iwamoto M, Takao C, Oba K, et al. Leucine-rich alpha-2-glycoprotein 1 and angiotensinogen as diagnostic biomarkers for Kawasaki disease. PLoS ONE. 2021;16(9):e0257138. · doi:10.1371/journal.pone.0257138
- Kessel C, Kone-Paut I, Tellier S, et al. An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial. Res Squ. 2022;. https://doi.org/10.21203/rs.3.rs-1214443/v1. · doi:10.21203/rs.3.rs-1214443/v1
- Kim J, Kang S, Kim J, Kwon G, Koo S. Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab Med. 2013;33(1):52–9. · DOI
- Sarkar S, Cooney LA, Fox DA. The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol. 2010;159(3):225–37. · DOI
- Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–86. · DOI · Paper page
- Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, et al. Evaluation of serum leucine-rich alpha-2 glycoprotein as a new inflammatory biomarker of inflammatory bowel disease. Mediators Inflamm. 2021;2021:8825374. · DOI
- Norkina O, Kaur S, Ziemer D, De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G1032–41. · DOI · Paper page
- Phua T, Sng MK, Tan EH, Chee DS, Li Y, Wee JW, et al. Angiopoietin-like 4 mediates colonic inflammation by regulating chemokine transcript stability via tristetraprolin. Sci Rep. 2017;7:44351. · DOI
- Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol. 2007;179(10):6988–7000. · DOI · Paper page
- Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol. 2021;56(6):560–9. · DOI
- Bini L, Magi B, Marzocchi B, Cellesi C, Berti B, Raggiaschi R, et al. Two-dimensional electrophoretic patterns of acute-phase human serum proteins in the course of bacterial and viral diseases. Electrophoresis. 1996;17(3):612–6. · DOI · Paper page
- Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, et al. Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis. Sci Rep. 2020;10(1):3384. · DOI
- Singer SN, Ndumnego OC, Kim RS, Ndung’u T, Anastos K, French A, et al. Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine. 2022. https://doi.org/10.1016/j.ebiom.2021.103787. · DOI
- Kentsis A, Lin YY, Kurek K, Calicchio M, Wang YY, Monigatti F, et al. Discovery and validation of urine markers of acute pediatric appendicitis using high-accuracy mass spectrometry. Ann Emerg Med. 2010;55(1):62-70.e4. · DOI
- Hashida T, Nakada TA, Satoh M, Tomita K, Kawaguchi R, Nomura F, et al. Proteome analysis of hemofilter adsorbates to identify novel substances of sepsis: a pilot study. J Artif Organs. 2017;20(2):132–7. · DOI
- Chen JH, Chang YW, Yao CW, Chiueh TS, Huang SC, Chien KY, et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc Natl Acad Sci U S A. 2004;101(49):17039–44. · DOI
- Yang W, Laeyendecker O, Wendel SK, Zhang B, Sun S, Zhou JY, et al. Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors. Theranostics. 2014;4(12):1153–63. · DOI
- Demichev V, Tober-Lau P, Nazarenko T, Lemke O, Kaur Aulakh S, Whitwell HJ, et al. A proteomic survival predictor for COVID-19patients in intensive care. PLOS Digit Health. 2022;1(1):e0000007. · DOI
- Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.138999. · DOI · Paper page
- Wang Y, Chen C, Hua Q, Wang L, Li F, Li M, et al. Downregulation of leucinerichalpha2glycoprotein 1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma. Oncol Rep. 2017;37(3):1503–10. · doi:10.3892/or.2017.5377
- Zhang N, Ren Y, Wang Y, Zhao L, Wang B, Ma N, et al. LRG1 suppresses migration and invasion of esophageal squamous cell carcinoma by modulating epithelial to mesenchymal transition. J Cancer. 2020;11(6):1486–94. · DOI
- Zhang Y, Luo Q, Wang N, Hu F, Jin H, Ge T, et al. LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells. Med Oncol. 2015;32(5):146. · DOI
- Takemoto N, Serada S, Fujimoto M, Honda H, Ohkawara T, Takahashi T, et al. Leucine-rich alpha-2-glycoprotein promotes TGFbeta1-mediated growth suppression in the Lewis lung carcinoma cell lines. Oncotarget. 2015;6(13):11009–22. · DOI
- Andersen JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, et al. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res. 2010;3:21. · DOI
- Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, et al. Clinicopathological significance of leucine-rich alpha2-glycoprotein-1 in sera of patients with pancreatic cancer. Pancreas. 2015;44(1):93–8. · DOI
- Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C, et al. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics. 2011. https://doi.org/10.1074/mcp.M111.010298. · DOI
- Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer. 2011;105(9):1370–8. · DOI
- Sun DC, Shi Y, Wang LX, Lv Y, Han QL, Wang ZK, et al. Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis. Oncotarget. 2017;8(39):66550–8. · DOI
- Wang CH, Li M, Liu LL, Zhou RY, Fu J, Zhang CZ, et al. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget. 2015;6(39):42118–29. · doi:10.18632/oncotarget.5967
- Wu J, Xie X, Nie S, Buckanovich RJ, Lubman DM. Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis. J Proteome Res. 2013;12(7):3342–52. · doi:10.1021/pr400169n
- Yamamoto M, Takahashi T, Serada S, Sugase T, Tanaka K, Miyazaki Y, et al. Overexpression of leucine-rich alpha2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Sci. 2017;108(10):2052–60. · DOI
- Zhang Q, Huang R, Tang Q, Yu Y, Huang Q, Chen Y, et al. Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter. Onco Targets Ther. 2018;11:2745–52. · DOI
- Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, et al. Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw266. · DOI
- Linden M, Lind SB, Mayrhofer C, Segersten U, Wester K, Lyutvinskiy Y, et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics. 2012;12(1):135–44. · DOI · Paper page
- Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, et al. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS ONE. 2015;10(3):e0121112. · DOI
- Zhang H, Cao J, Li L, Liu Y, Zhao H, Li N, et al. Identification of urine protein biomarkers with the potential for early detection of lung cancer. Sci Rep. 2015;5:11805. · DOI
- Cavalcante Mde S, Torres-Romero JC, Lobo MD, Moreno FB, Bezerra LP, Lima DS, et al. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia. Biomark Res. 2016;4:1. · DOI
- Li Z, Zeng C, Nong Q, Long F, Liu J, Mu Z, et al. Exosomal leucine-rich-alpha2-glycoprotein 1 derived from non-small-cell lung cancer cells promotes angiogenesis via TGF-beta signal pathway. Mol Ther Oncolytics. 2019;14:313–22. · DOI
- Surinova S, Choi M, Tao S, Schuffler PJ, Chang CY, Clough T, et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med. 2015;7(9):1166–78. · DOI
- Miyauchi E, Furuta T, Ohtsuki S, Tachikawa M, Uchida Y, Sabit H, et al. Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics. PLoS ONE. 2018;13(3):e0193799. · DOI
- Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, Wang H, et al. Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila). 2012;5(4):655–64. · DOI
- Zhong D, He G, Zhao S, Li J, Lang Y, Ye W, et al. LRG1 modulates invasion and migration of glioma cell lines through TGF-beta signaling pathway. Acta Histochem. 2015;117(6):551–8. · DOI
- Zhong D, Zhao S, He G, Li J, Lang Y, Ye W, et al. Stable knockdown of LRG1 by RNA interference inhibits growth and promotes apoptosis of glioblastoma cells in vitro and in vivo. Tumour Biol. 2015;36(6):4271–8. · DOI
- Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer. 2011;105(11):1759–67. · DOI
- Zhang J, Zhu L, Fang J, Ge Z, Li X. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1alpha activation. J Exp Clin Cancer Res. 2016;35:29. · DOI
- Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223(2):205–18. · DOI · Paper page
- Sun D, Kar S, Carr BI. Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. Cancer Lett. 1995;89(1):73–9. · doi:10.1016/0304-3835(95)90160-4
- Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–84. · DOI · Paper page
- Teuwen LA, De Rooij L, Cuypers A, Rohlenova K, Dumas SJ, Garcia-Caballero M, et al. Tumor vessel co-option probed by single-cell analysis. Cell Rep. 2021;35(11):109253. · DOI
- Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, et al. Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. Nat Commun. 2018;9(1):2705. · DOI
- Rafii S, Butler JM, Ding B-S. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316–25. · DOI · Paper page
- Alsina-Sanchis E, Mülfarth R, Fischer A. Control of tumor progression by angiocrine factors. Cancers. 2021;13(11):2610. · DOI
- Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science. 2019;365(6453):544–5. · DOI · Paper page
- Miyajima M, Nakajima M, Motoi Y, Moriya M, Sugano H, Ogino I, et al. Leucine-rich alpha2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLoS ONE. 2013;8(9):e74453. · DOI
- Nakajima M, Miyajima M, Ogino I, Watanabe M, Hagiwara Y, Segawa T, et al. Brain localization of leucine-rich alpha2-glycoprotein and its role. Acta Neurochir Suppl. 2012;113:97–101. · doi:10.1007/978-3-7091-0923-6_20
- Li X, Miyajima M, Jiang C, Arai H. Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus. Neurosci Lett. 2007;413(2):141–4. · DOI
- Ge X, Zhang Y, Zuo Y, Israr M, Li B, Yu P, et al. Transcriptomic analysis reveals the molecular mechanism of Alzheimer-related neuropathology induced by sevoflurane in mice. J Cell Biochem. 2019;120(10):17555–65. · DOI
- Zheng R, Zhang ZH, Zhao YX, Chen C, Jia SZ, Cao XC, et al. Transcriptomic insights into the response of the olfactory bulb to selenium treatment in a mouse model of alzheimer’s disease. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20122998. · DOI
- Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir. 2006;148(8):859–64. · DOI
- Lolansen SD, Rostgaard N, Oernbo EK, Juhler M, Simonsen AH, MacAulay N. Inflammatory markers in cerebrospinal fluid from patients with hydrocephalus: a systematic literature review. Dis Markers. 2021;2021:8834822. · DOI
- Douglas MR, Daniel M, Lagord C, Akinwunmi J, Jackowski A, Cooper C, et al. High CSF transforming growth factor beta levels after subarachnoid haemorrhage: association with chronic communicating hydrocephalus. J Neurol Neurosurg Psychiatry. 2009;80(5):545–50. · DOI
- Kitazawa K, Tada T. Elevation of transforming growth factor-beta 1 level in cerebrospinal fluid of patients with communicating hydrocephalus after subarachnoid hemorrhage. Stroke. 1994;25(7):1400–4. · DOI
- Galbreath E, Kim SJ, Park K, Brenner M, Messing A. Overexpression of TGF-beta 1 in the central nervous system of transgenic mice results in hydrocephalus. J Neuropathol Exp Neurol. 1995;54(3):339–49. · DOI
- Wyss-Coray T, Feng L, Masliah E, Ruppe MD, Lee HS, Toggas SM, et al. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol. 1995;147(1):53–67.
- Zhan Y, Yang YT, You HM, Cao D, Liu CY, Zhou CJ, et al. Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in post-stroke depression. Eur Psychiatry. 2014;29(5):307–15. · DOI
- Jin J, Sun H, Liu D, Wang H, Liu Q, Chen H, et al. LRG1 promotes apoptosis and autophagy through the TGFbeta-smad1/5 signaling pathway to exacerbate ischemia/reperfusion injury. Neuroscience. 2019;413:123–34. · DOI
- Anand KS, Dhikav V. Hippocampus in health and disease: an overview. Ann Indian Acad Neurol. 2012;15(4):239–46. · DOI · Paper page
- Stankiewicz AM, Goscik J, Majewska A, Swiergiel AH, Juszczak GR. The Effect of Acute and Chronic Social Stress on the Hippocampal Transcriptome in Mice. PLoS ONE. 2015;10(11):e0142195. · DOI · Paper page
200 of 240 shown
Metadata
- Authors
- Camilli, C., Hoeh, A. E., De Rossi, G., Moss, S. E., & Greenwood, J.
- Venue
- Journal of Biomedical Science
- Published
- 2022-01-21
- Volume
- 29
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1021-7770 (ISSN-L)
- 1423-0127
- OpenAlex
- W4207069970
- Cited by
- 187
- References
- 22
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- diamond
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Wellcome Trust (206413/B/17/Z)
- UKRI/Medical Research Council UK (G1000466)
- The British Heart Foundation (PG/16/50/32182)
- Diabetes UK (18/0005856)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LRG1: an emerging player in disease pathogenesis. https://app.cochat.ai/papers/10.1186/s12929-022-00790-6
- The paper
- Camilli, C., Hoeh, A. E., De Rossi, G., Moss, S. E., & Greenwood, J. (2022). LRG1: an emerging player in disease pathogenesis. Journal of Biomedical Science. https://doi.org/10.1186/s12929-022-00790-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.